Date: Sunday, May 3, 2015
Session Time: 5:30pm-6:30pm
Presentation Time: 5:30pm-6:30pm
Location: Exhibit Hall E
Belatacept offers a new option for renal allograft recipients who are suffering from side effects of calcineurin inhibitor or mTOR. Such a conversion may result in renal and extrarenal benefits. Today the effect of this new immunosuppressant on the immunophenotype is largely unknown. Therefore we prospectively performed flow cytometric immunophenotyping of especially T-helper cells. In total we were able to fully investigate a potential immunophenotype change in 5 patients after CNI withdrawal (n=3) or conversion from mTOR to Belatacept (n=2). Stable clinical courses were observed in the patients and no rejection episodes occurred. Cells were analyzed at time points pre conversion, 1 month, 3 months, 6 months and 12 months post conversion. The percentage of central memory, naïve, effector memory and terminally differentiated effector memory CD4+ T-cells was determined. CD28, CD25, CD69 and CD71 expression on CD4+ T-cells were measured ex vivo and also after 3 days of ConcanavalinA stimulation. Additionally intracellular cytokines IFNgamma and IL-2 were measured after PMA/Ionomycin cell stimulation. The expression of activation markers and intracellular cytokines as well as the percentage of T-helper cell subsets did not change during the observation period. Therefore the conversion of CNI or mTOR to belatacept seems to have no impact on the immunophenotype of CD4+ T-cells in patients after kidney transplantation.
To cite this abstract in AMA style:Matz M, Fabritius K, Lorkowski C, Liu J, Brakemeier S, Unterwalder N, Neumayer H-H, Budde K. Conversion to Belatacept After Kidney Transplantation Does Not Alter Immunophenotype [abstract]. Am J Transplant. 2015; 15 (suppl 3). https://atcmeetingabstracts.com/abstract/conversion-to-belatacept-after-kidney-transplantation-does-not-alter-immunophenotype/. Accessed June 12, 2021.
« Back to 2015 American Transplant Congress